-
Review Article
-
J Mult Scler. 2019;10(2):27-31. Published online September 1, 2019.
- 다발성경화증의 최신지견: 2018-2019년
-
박기홍
-
충남대학교병원 신경과
-
- What’s New in Multiple Sclerosis: 2018-2019
-
Kee Hong Park
-
Department of Neurology, Chungnam National University Hospital, Daejeon, Korea
-
- Abstract
- Multiple sclerosis (MS) is a demyelinating and inflammatory disease of the central nervous system. Most patients develop MS in the form of relapsing-remitting multiple sclerosis (RRMS). Patients with RRMS also develop neurological deficits over time and progress to secondary progressive MS. A mi- nority of patients develop primary progressive MS, which shows a progressive clinical course from the initial phase of the disease. Development of disease modifying therapies has been focused on RRMS and treatment for progressive MS (secondary progressive multiple sclerosis and primary pro-gressive multiple sclerosis) has been limited. There have been many advances in progressive MS treatment in recent years. This review summarizes recent therapeutic research and explores the neurofilament light chain, which is drawing attention as a biomarker. Journal of Multiple Sclerosis 10(2):27-31, 2019
Keywords :Multiple sclerosis, Demyelinating diseases, Neurofilament proteins
